Pharmacodynamic profile of bisoprolol, a new beta 1-selective adrenoceptor antagonist - PubMed (original) (raw)

Clinical Trial

Pharmacodynamic profile of bisoprolol, a new beta 1-selective adrenoceptor antagonist

G Leopold et al. Br J Clin Pharmacol. 1986 Sep.

Abstract

The pharmacodynamic profile of bisoprolol, a new beta 1-selective adrenoceptor antagonist, was investigated in four independent studies including 36 healthy male volunteers. Using the model of exercise-induced tachycardia (ET) the beta-adrenoceptor blocking properties of bisoprolol (2.5-40 mg) were examined in comparison to metoprolol (50 and 100 mg), propranolol (40 and 80 mg) and atenolol (50 and 100 mg). The maximal reduction of ET was achieved between 1 and 4 h following single oral administration. The dose-response relationship using individual maximal reduction of ET showed, on a molar basis, that bisoprolol is about 5, 7 and 10 times more effective than propranolol, atenolol and metoprolol, respectively. In the model of insulin-induced hypoglycaemia bisoprolol behaved as a beta 1-selective adrenoceptor antagonist. There was a good correlation (r = 0.94) between the log bisoprolol concentration and the reduction in exercise-induced tachycardia. Bisoprolol is a potent new cardioselective beta-adrenoceptor antagonist with a competitive action at beta 1-adrenoceptors.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Circulation. 1967 Jun;35(6):1073-83 - PubMed
    1. Eur J Clin Pharmacol. 1986;29(5):517-21 - PubMed
    1. Acta Pharmacol Toxicol (Copenh). 1975;36(Suppl 5):69-75 - PubMed
    1. Br Med J. 1976 Jul 31;2(6030):272-3 - PubMed
    1. Br Med J. 1976 Aug 21;2(6033):447-9 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources